

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)



(10) International Publication Number
WO 2022/218324 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C12N 15/13 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/CN2022/086525

(22) International Filing Date:

13 April 2022 (13.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/087278

14 April 2021 (14.04.2021) CN

(71) Applicant: SUZHOU TRANSCENTA THERAPEUTICS CO., LTD. [CN/CN]; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN).

(72) Inventors: QIAN, Xueming; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). LI, Zhenping; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). LI, Hongjun; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN). GUO, Huanhuan; B6-501, 218 Xinghu Street, Suzhou, Jiangsu 215123 (CN).

(74) Agent: JUN HE LAW OFFICES; 20/F, China Resources Building 8 Jianguomenbei Avenue, Beijing 100005 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: NOVEL ANTI-HVEGFR2 ANTIBODIES

(57) Abstract: Provided are anti-hVEGFR2 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

WO 2022/218324 A1